Acute lymphoblastic leukaemia

The Pharmaceutical Benefits Scheme (PBS) subsidises dasatinib, imatinib mesilate and ponatinib for patients with acute lymphoblastic leukaemia (ALL).

Treatment with dasatinib, imatinib mesilate and ponatinib can be subsidised through the PBS under section 85 of the National Health Act 1953 for patients with acute lymphoblastic leukaemia.

Patient eligibility

Patients must meet the relevant criteria in the restrictions and be eligible for the PBS.

The Schedule of Pharmaceutical Benefits on the PBS website outlines restrictions for prescribing dasatinib, imatinib mesilate and ponatinib.

Applications

Pathology reports

All applications need a pathology report confirming eligibility for treatment.

Initial - imatinib mesilate

Make all initial applications for authority approval to prescribe imatinib mesilate for the treatment of ALL in writing and:

All applications must include a completed:

Imatinib mesilate is available as PBS subsidised therapy for induction or consolidation of newly diagnosed patients with ALL. For patients who express the Philadelphia chromosome or the transcript BCR-ABL, and must be in combination with chemotherapy.

Continuing treatment - imatinib mesilate

Imatinib mesilate is available for a lifetime maximum of 24 months of PBS subsidised continuing treatment.

Initial treatment - dasatinib

Make all initial applications for authority approval to prescribe dasatinib for the treatment of ALL in writing and:

All applications must include a completed:

Dasatinib, as monotherapy, is available as PBS subsidised therapy for patients with ALL. Patients must express the Philadelphia chromosome or the transcript BCR-ABL and have failed treatment with:

  • chemotherapy and imatinib mesilate, and
  • allogeneic haemopoietic stem cell transplantation where appropriate

Continuing treatment - dasatinib

Patients can receive PBS subsidised continuing treatment with dasatinib if they previously had an authority prescription for this condition and do not have a progressive disease.

Applications for continuing treatment can be made by calling the PBS Complex Drugs Programs enquiry line.

Initial treatment - ponatinib

Make all initial applications for authority approval to prescribe ponatinib for the treatment of ALL in writing and:

All applications must include a completed:

Ponatinib, as monotherapy, is available as PBS subsidised therapy to treat relapsed or refractory Philadelphia chromosome positive (Ph+) ALL in patients with the T315i mutation.

Patients must have failed treatment with:

  • chemotherapy, with or without another tyrosine kinase inhibitor (TKI), and
  • allogeneic haemopoietic stem cell transplantation, where appropriate

Continuing treatment - ponatinib

Patients can receive PBS subsidised continued treatment with ponatinib if they previously had an authority prescription for this condition and do not have a progressive disease.

Apply for continuing treatment with ponatinib by calling the PBS Complex Drugs enquiry line.

Further information

For more information call the PBS Complex Drugs Programs enquiry line.

Page last updated: 1 February 2017

This information was printed Monday 20 February 2017 from humanservices.gov.au/health-professionals/enablers/acute-lymphoblastic-leukaemia It may not include all of the relevant information on this topic. Please consider any relevant site notices at humanservices.gov.au/siteinformation when using this material.